Attendee search 

上海元亨祥股权投资基金集团有限公司（简称“元亨祥基金”），2012年8月落户于上海陆家嘴国际金融中心，2014年4月在中国证券投资基金业协会登记为“私募基金管理人”，下设元杏资产（其他类私募基金）、祥乾投资（股权类私募基金）、王道资产（证券类私募基金）。

作为风控型资产管理专家，元亨祥基金始终秉承“专业创造价值，安全方得安心”的品牌理念，顺应国家发展战略，携手世界500强名企太平洋建设、中国建筑、中冶天工等交易对手，积极引导社会资本投资“大基建、大康养、大文旅”领域，累计投资项目超过300个、累计投资规模超过300亿、累计撬动项目总规模超过3000亿，投资足迹遍布全国；同时，凭借投向明确、风控周密、期限合理、业绩领先、产品丰富五大优势，持续专注做好基建投资基金、证券投资基金、特色小镇基金、不动产基金、产业投资基金五大系列基金，为客户倾力打造专属投融资服务。

3SBio

InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, New Jersey, and Boston.

MAVIE Technologies is an investment banking boutique in Chinese-Western healthcare transactions providing commercially-focused, end to end advice to maximize deal certainty and increase the intended value of transactions. Our team combines deal structuring sophistication and experience - whether it is private placement, secondary shares sale, joint-venture, licensing or M&A - with deep Chinese healthcare insights, strategic thinking and proprietary access. We add unique value in visualizing, negotiating and closing the deal.

Armoured hold the Tianyi Group layout of science and technology investment capital investment platform. Armoured capital in order to create long-term value for the purpose, committed to accelerate the transformation of scientific and technological industry and fall to the ground, accelerate the development of innovative enterprise, and industry potential industry and change. So far, has invested Zephyrm Biotechnologies, Milky Way motivation, CSTshen, companies such as the future and will continue to pay attention to the capitalization of the business process and industry, seek the change from a single financial investment to the strategy of diversifying investment.

Humanwell is the market leader in anaesthetics/analgesics, fertility regulation drugs, and Uyghur medicine in Asia. It is also a major player with expanding product portfolio and market shares in treating central nerve system, respiratory and dermatological diseases in China.

Harbour BioMed is a global, clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in the areas of oncology and immunological diseases to address unmet patient’s needs.

TransThera Biosciences is a Nanjing based biotech, founded in 2016, focusing on research and development of small molecules in oncology, inflammation, and cardiovascular diseases. Four assets have entered into global clinical development in past 4 years.

pharmaceutical company

Henlius (2696.HK) is a leading biopharmaceutical company in China with the vision to offer high-quality, affordable and innovative biologics for patients worldwide with a focus on oncology and autoimmune diseases. Since its inception in 2010, Henlius has built an integrated and efficient global R&D platform with key facilities in Shanghai, Taipei and California, and commercial office in Frankfurt. The three R&D centers closely collaborate with each other to ensure a highly productive and cost-efficient R&D process.
Starting from biosimilar, Henlius presses forward with novel mAb products and immuno-oncology combination therapies with proprietary anti-PD-1 and PD-L1 mAbs as backbone. Henlius establishes a diversified product pipeline of biosimilars, bio-innovative drugs and combination therapies, and builds an integrated platform covering the whole product lifecycle including R&D, commercial-scale production and commercialization.

Keywords : Cancer, Oncology, Biologics, Biosimilar, BioInnovative, Biobetter, Monoclonal Antibody, Mabs, Tumors, Immuno oncology, PD1, PD-L1, EGFR, VEGF, HER2,